title: miR-505-5p and miR-193b-3p: potential biomarkers of imatinib response in patients with chronic myeloid leukemia.
authors.affiliation: a Department of Pharmacology , All India Institute of Medical Sciences , New Delhi , India.
authors.forename: Suganthi S
authors.initials: SS
authors.lastname: Ramachandran
authors.affiliation: b School of Life Sciences, Jawaharlal Nehru University , New Delhi , India.
authors.forename: Pamchui
authors.initials: P
authors.lastname: Muiwo
authors.affiliation: c Department of Cancer Cell and Molecular Biology , University of Massachusetts Medical School , Worcester , MA , USA.
authors.forename: Hafiz M
authors.initials: HM
authors.lastname: Ahmad
authors.affiliation: d Department of Biostatistics , All India Institute of Medical Sciences , New Delhi , India.
authors.forename: Ravindra Mohan
authors.initials: RM
authors.lastname: Pandey
authors.affiliation: a Department of Pharmacology , All India Institute of Medical Sciences , New Delhi , India.
authors.forename: Surender
authors.initials: S
authors.lastname: Singh
authors.affiliation: e Department of Medical Oncology , Dr. BRA IRCH, All India Institute of Medical Sciences , New Delhi , India.
authors.forename: Sameer
authors.initials: S
authors.lastname: Bakhshi
authors.affiliation: e Department of Medical Oncology , Dr. BRA IRCH, All India Institute of Medical Sciences , New Delhi , India.
authors.forename: Lalit
authors.initials: L
authors.lastname: Kumar
authors.affiliation: b School of Life Sciences, Jawaharlal Nehru University , New Delhi , India.
authors.forename: Alok
authors.initials: A
authors.lastname: Bhattacharya
authors.affiliation: a Department of Pharmacology , All India Institute of Medical Sciences , New Delhi , India.
authors.forename: Yogendra Kumar
authors.initials: YK
authors.lastname: Gupta
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014408:Biomarkers, Tumor; D002648:Child; D019008:Drug Resistance, Neoplasm / Q000235:genetics; D005260:Female; D020869:Gene Expression Profiling; D015973:Gene Expression Regulation, Leukemic; D006801:Humans; D000068877:Imatinib Mesylate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000175:diagnosis / Q000188:drug therapy* / Q000235:genetics* / Q000401:mortality; D008297:Male; D035683:MicroRNAs / Q000235:genetics*; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C546818:MIRN193 microRNA, human; C574053:MIRN505 microRNA, human; D035683:MicroRNAs; D047428:Protein Kinase Inhibitors; D000068877:Imatinib Mesylate